Novartis, MMV announce positive data from phase II/III CALINA study of Coartem to treat babies <5 kg with malaria
Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, demonstrating that a novel formulation of Coartem (artemether-lumefantrine) developed for babies weighing less than 5kg with malaria has the …